Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02666378 · ClinicalTrials.gov registry record
Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer
A clinical trial of Breast Cancer, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT02666378 is a study of Breast Cancer that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 50 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02666378, a study of Breast Cancer, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the treatment of breast cancer.
Conditions Studied
Interventions
- OTHER Cardiac Magnetic Resonance Imaging (CMR)
- OTHER Echocardiogram (ECHO)
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2024-07-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02666378
The ClinicalTrials.gov registry entry for NCT02666378 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cardiac Magnetic Resonance Imaging (CMR) is the first listed.
NCT02666378 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02666378 about?
NCT02666378 is a clinical study titled "Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer". This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the treatment of breast cancer.
What is the current status of trial NCT02666378?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2018-09-10. Estimated completion is 2024-07-10.
What conditions does trial NCT02666378 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02666378?
The interventions under investigation include: Cardiac Magnetic Resonance Imaging (CMR) (OTHER), Echocardiogram (ECHO) (OTHER).
Who is sponsoring clinical trial NCT02666378?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02666378 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.